Strain Information | |
---|---|
Image | |
BRC No. | RBRC01737 |
Type | Targeted Mutation |
Species | Mus musculus |
Strain name | B6;129S4-Dnmt1<tm2Enl> |
Former Common name | Dnmt<1c>, Dnmt<c>, Dnmt1<tm2Enl> |
H-2 Haplotype | |
ES Cell line | J1 [129S4/SvJae] |
Background strain | |
Appearance | |
Strain development | |
Strain description | |
Colony maintenance | |
References | De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells. Lei H, Oh S P, Okano M, Juttermann R, Goss K A, Jaenisch R, Li E Development, 122, 3195-3205 (1996). 8898232 |
Health Report | |
---|---|
Examination Date / Room / Rack |
Gene | |||||||
---|---|---|---|---|---|---|---|
Gene Symbol | Gene Name | Chr. | Allele Symbol | Allele Name | Common Names | Promoter | Diseases Related to This Gene |
Dnmt1 | DNA methyltransferase 1 | 9 | Dnmt1 | targeted mutation 2, En Li | |||
neo | neomycin resistance gene (E. coli) | 9 | mouse phosphoglycerate kinase promoter (PGK promoter) |
Phenotype | |
---|---|
Annotation by Mammalian phenotyhpe ontology | more 4 phenotypes |
Detailed phenotype data |
Ordering Information | |
---|---|
Donor DNA | mouse phosphoglycerate kinase promoter (PGK promoter), E. coli neo, mouse Pgk1 polyA, mouse Dnmt1 genomic DNA |
Research application | |
Specific Term and Conditions | A. RECIPIENT must send a copy of the executed MTA between RECIPIENT and RIKEN BRC to: Massachusetts General Hospital c/o Partners Innovation, Attn: TAG/MGH MTA 2020A005592, 399 Revolution Drive/Ste 950E, Somerville,MA 02245, USA (phsmta@partners.org). B. Any publication or public disclosure of research results obtained by the use of the BIOLOGICAL RESOURCE shall cite Massachusetts General Hospital in Boston, MA as the source of the material. However, neither the name, trademark, service mark, logo nor other identifying characteristic ("Name") of MGH or any of its affiliates, or any of its or their respective directors, trustees, officers, appointees, employees, staff, representatives or agents, in any advertising, promotional or sales literature, publicity or in any document employed to obtain funds or financing without the prior written approval of the MGH Department of Public Affairs. C. In publishing research results obtained by the use of the BIOLOGICAL RESOURCE, a citation of the literature Development 1996 122:3195-3205 as designated by the DEPOSITOR is required. D. The use of the BIOLOGICAL RESOURCE is restricted to academic researchers in non-profit organizations for their internal research and educational purposes. E. The BIOLOGICAL RESOURCE shall not be used for commercial purposes. Any request for the BIOLOGICAL RESOURCE by a for-profit entity shall be referred to Massachusetts General Hospital through the Research and Licensing Office. F. Recipients shall assume all liability for their use, storage, handling and disposal of the BIOLOGICAL RESOURCE. The General Hospital Corporation d/b/a Massachusetts General Hospital will not be liable to the Recipients for any loss, claims, matters, damages, costs or liabilities relating to any third party actions, proceedings, investigations, or matters arising from any use, storage, handling, or disposal of the BIOLOGICAL RESOURCE by Recipient. |
Depositor | Masaki Okano (RIKEN) |
Strain Status | Frozen embryos Frozen sperm |
Strain Availability | Recovered litters from cryopreserved embryos (2 to 4 months) Cryopreserved sperm (within 1 month) Cryopreserved embryos (within 1 month) |
Additional Info. | Necessary documents for ordering:
Genotyping protocol -PCR- |
BRC mice in Publications |
---|
No Data |